11C-Methionine and 2-18F-Fluoro-2-Deoxy-D-Glucose PET Imaging in Patients With Progressive Prostate Cancer
- Measure the pharmacokinetics, whole body retention of isotope, and biodistribution of
C11-methionine and FDG by PET imaging and serial sampling of blood in men with
progressive prostate cancer.
- Explore metabolism of each PET scan by comparing the sensitivity of C11-methionine or
FDG by PET scanning in androgen independent prostate cancer metastases with the
sensitivity of C11-methionine or FDG in androgen dependent metastases on a site by site
- Compare C11-methionine and FDG PET scanning to standard of care diagnostic studies
which include the Tc 99m bone scan, computed tomography, and magnetic resonance
Patients fast for 6 hours prior to PET imaging with the exception of liberal water intake
which is encouraged. A two way catheter is placed in the urinary bladder, and continuous
isotonic saline irrigation is performed throughout scan acquisition to reduce the
interference in imaging lesions in the pelvic lymph nodes and adjacent pelvic bones caused
by radiation excreted in urine held in the bladder.
Each patient receives C11-methionine intravenously. PET imaging begins immediately after
injection for approximately 60 minutes total using standard imaging procedures. Immediately
following the completion of imaging after C11-methionine administration, each patient
receives FDG intravenously. PET imaging begins approximately 45 minutes thereafter for
approximately 60 minutes using standard imaging procedures.
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Steven M. Larson, MD
Memorial Sloan-Kettering Cancer Center
United States: Institutional Review Board
|Memorial Sloan-Kettering Cancer Center||New York, New York 10021|